BriaCell Expands Pipeline with Ovarian Cancer Immunotherapy Candidate Bria-OVA+
BCTX is trading near its 52-week low of $3.6 (14% above the low).
Summary
BriaCell Therapeutics has announced the expansion of its pipeline to include Bria-OVA+™, a new personalized, off-the-shelf, cell-based immunotherapy candidate for ovarian cancer. This strategic move leverages the company's Bria-OTS+™ platform and follows recent positive updates on its Bria-ABC Phase 3 study for breast cancer and manufacturing completion for Bria-PROS+™ for prostate cancer. For a clinical-stage biotech with a small market capitalization, adding a new candidate for a significant unmet medical need like ovarian cancer is a material positive development, demonstrating active pipeline progression despite a recent going concern warning. Investors will now watch for further preclinical data and the initiation of clinical trials for Bria-OVA+.
At the time of this announcement, BCTX was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $3.60 to $37.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.